Skip to Main Content

Paper Details

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
J Immunother Cancer
23
2021
Author NameAffiliation
Philippe L BedardPrincess Margaret Hospital Cancer Centre
  • 1 - 1

Datasets

Release 1.2